United Capital Financial Advisors’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.81M Sell
19,972
-21,227
-52% -$1.78M 0.01% 608
2026
Q1
$3.3M Buy
41,199
+1,079
+3% +$89K 0.02% 453
2025
Q4
$3.42M Buy
40,120
+1,659
+4% +$136K 0.02% 415
2025
Q3
$2.99M Buy
38,461
+2,494
+7% +$195K 0.02% 381
2025
Q2
$2.81M Buy
35,967
+4,707
+15% +$351K 0.02% 376
2025
Q1
$2.27M Buy
31,260
+6,401
+26% +$458K 0.02% 402
2024
Q4
$1.84M Buy
24,859
+9,779
+65% +$684K 0.02% 434
2024
Q3
$995K Sell
15,080
-2,422
-14% -$176K 0.01% 541
2024
Q2
$1.62M Sell
17,502
-11,880
-40% -$1.05M 0.01% 446
2024
Q1
$2.81M Sell
29,382
-1,324
-4% -$111K 0.02% 369
2023
Q4
$2.34M Sell
30,706
-4,913
-14% -$342K 0.02% 387
2023
Q3
$2.47M Sell
35,619
-3,510
-9% -$282K 0.02% 396
2023
Q2
$3.69M Sell
39,129
-1,405
-3% -$122K 0.02% 357
2023
Q1
$3.35M Buy
40,534
+3,271
+9% +$257K 0.02% 371
2022
Q4
$2.78M Buy
37,263
+22,295
+149% +$1.72M 0.02% 424
2022
Q3
$1.24M Sell
14,968
-3,490
-19% -$336K 0.01% 568
2022
Q2
$1.75M Buy
18,458
+2,420
+15% +$251K 0.01% 516
2022
Q1
$1.89M Sell
16,038
-1,500
-9% -$168K 0.01% 530
2021
Q4
$2.27M Buy
17,538
+55
+0.3% +$6.42K 0.01% 510
2021
Q3
$1.98M Sell
17,483
-13,094
-43% -$1.49M 0.01% 527
2021
Q2
$3.17M Buy
30,577
+949
+3% +$89.5K 0.02% 453
2021
Q1
$2.48M Sell
29,628
-3,085
-9% -$261K 0.01% 466
2020
Q4
$2.98M Sell
32,713
-2,545
-7% -$211K 0.02% 431
2020
Q3
$2.81M Sell
35,258
-11,060
-24% -$863K 0.02% 433
2020
Q2
$3.2M Sell
46,318
-59,210
-56% -$4.21M 0.02% 429
2020
Q1
$6.63M Buy
105,528
+24,963
+31% +$1.8M 0.05% 298
2019
Q4
$6.26M Buy
80,565
+78
+0.1% +$6.09K 0.04% 382
2019
Q3
$5.9M Sell
80,487
-10,248
-11% -$720K 0.04% 374
2019
Q2
$5.59M Sell
90,735
-393
-0.4% -$23.8K 0.04% 401
2019
Q1
$5.81M Buy
91,128
+1,860
+2% +$106K 0.04% 384
2018
Q4
$4.56M Buy
89,268
+2,034
+2% +$103K 0.04% 400
2018
Q3
$5.06M Buy
87,234
+8,979
+11% +$439K 0.04% 430
2018
Q2
$3.8M Buy
78,255
+6,252
+9% +$292K 0.03% 465
2018
Q1
$3.35M Buy
72,003
+46,821
+186% +$2.03M 0.03% 472
2017
Q4
$946K Sell
25,182
-16,152
-39% -$593K 0.01% 794
2017
Q3
$1.51M Buy
41,334
+7,830
+23% +$299K 0.01% 652
2017
Q2
$1.32M Buy
33,504
+8,454
+34% +$309K 0.01% 688
2017
Q1
$785K Sell
25,050
-24,258
-49% -$759K 0.01% 809
2016
Q4
$1.54M Buy
49,308
+2,310
+5% +$74.8K 0.02% 623
2016
Q3
$1.89M Sell
46,998
-1,044
-2% -$39.3K 0.02% 601
2016
Q2
$1.6M Buy
48,042
+33,342
+227% +$1.14M 0.02% 610
2016
Q1
$432K Buy
14,700
+894
+6% +$24.7K ﹤0.01% 919
2015
Q4
$363K Sell
13,806
-16,806
-55% -$436K ﹤0.01% 966
2015
Q3
$725K Buy
30,612
+6,972
+29% +$168K 0.01% 782
2015
Q2
$561K Buy
23,640
+4,422
+23% +$99.8K 0.01% 876
2015
Q1
$406K Sell
19,218
-7,854
-29% -$176K 0.01% 985
2014
Q4
$575K Sell
27,072
-2,796
-9% -$56.2K 0.01% 781
2014
Q3
$509K Buy
+29,868
New +$471K 0.01% 792
2014
Q2
Sell
-30,672
Closed -$379K 835
2014
Q1
$379K Buy
+30,672
New +$354K 0.01% 713
2013
Q4
Sell
-32,508
Closed -$377K 682
2013
Q3
$377K Sell
32,508
-14,232
-30% -$167K 0.01% 509
2013
Q2
$523K Buy
+46,740
New +$553K 0.01% 501

Other funds holding EW

United Capital Financial Advisors's EW Position: Q2 2026 in Review

United Capital Financial Advisors reduced its Edwards Lifesciences (EW) stake by 52% in Q2 2026, selling an estimated $1.78M and leaving 19,972 shares worth $1.81M. The position accounts for 0.01% of the portfolio, ranked #608.

United Capital Financial Advisors first reported a position in EW in Q2 2013 and has held it in 51 quarters since. The position peaked at $6.63M in Q1 2020. 1,327 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • United Capital Financial Advisors held 19,972 shares of Edwards Lifesciences worth $1.81M as of Q2 2026.
  • United Capital Financial Advisors sold 21,227 Edwards Lifesciences shares in Q2 2026, an estimated $1.78M.
  • Edwards Lifesciences made up 0.01% of United Capital Financial Advisors's portfolio in Q2 2026, its #608 holding.
  • United Capital Financial Advisors first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 51 quarters since.
  • United Capital Financial Advisors's Edwards Lifesciences position peaked at $6.63M in Q1 2020.
  • 1,327 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on United Capital Financial Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.